Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07492524). This is a study registration, not published results. Lead sponsor: Jiangsu Taizhou People's Hospital. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 942 participants (ESTIMATED). Conditions: Atrial Fibrillation, Heart Failure. Interventions: OTHER: Village-Doctor Led Integrated Care; OTHER: Usual Care. Primary outcome measures: Primary Outcome of Phase 1: Change in MAGGIC Heart Failure Risk Score , Baseline to 12 months; Primary Outcome of Phase 2: Composite Cardiovascular Endpoint , 36 months after baseline; Primary Outcome of Extension Study: Composite cardiovascular endpoint , 72 months after baseline. Brief summary: The primary objective is to determine whether a telemedicine-supported, village doctor-led integrated management model, AF-HF comorbidity ABC pathway and enhanced patient education, improves clinical outcomes compared with usual care among rural residents aged 65-80 years with AF and HF. The trial will evaluate whether integrated management reduces the MAGGIC HF risk score at 12 months (phase 1) and whether it reduces a composite cardiovascular endpoint, including cardiovascular death, ischemic or hemorrhagic stroke, hospitalization for worsening heart failure or acute coronary syndrome, and emergency visits due to atrial fibrillation over 36 months (phase 2). An extended observational follow-up, the composite cardiovascular endpoint observational follow-up study, will be conducted at Year 6 to evaluate long-term effects.